The DOI matches its Crossref record; 35 of the 40 references it cites were found in a registry or an index.
Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study
Abstract
Background The glucagon-like peptide-1 analog liraglutide increases heart rate and may be associated with more cardiac events in chronic heart failure (CHF) patients. We studied whether this could be ascribed to effects on myocardial glucose uptake (MGU), myocardial blood flow (MBF) and MBF reserve (MFR). Methods and results CHF patients with left ventricular ejection fraction ≤45% and without type 2 diabetes were randomized to liraglutide (N = 18) 1.8 mg once daily or placebo (N = 18) for 24 weeks in a double-blinded design. Changes in MGU during an oral glucose tolerance test (OGTT) and changes in MBF and MFR from baseline to follow-up were measured quantitatively by 18 F-FDG and 15 O-H 2 O positron emission tomography. Compared with placebo, liraglutide reduced weight (P = 0.03), HbA1c (P = 0.03) and the 2-hour glucose value during the OGTT (P = 0.004). Despite this, changes in MGU (P = 0.98), MBF (P = 0.76) and MFR (P = 0.89) from baseline to follow-up did not differ between groups. Furthermore, there was no association between the level of insulin resistance at baseline and changes in MGU in patients treated with liraglutide. Conclusion Liraglutide did not affect MGU, MBF, or MFR in non-diabetic CHF patients. Any potential increase in cardiac events in these patients seems not to involve changes in MGU, MBF, or MFR. Trial registration Trial registry: http://www.ClinicalTrials.org . Identifier: NCT01472640. Url: https://clinicaltrials.gov/ct2/show/NCT01472640?term=NCT0147…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We show readers that GLP-1RAs have also been found to significantly reduce the risks of heart failure, atherosclerosis (AS), and hypertension, highlighting their broad therapeutic potential.16–19”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [18]
In the citing paper
“Moreover, these agents promote hemodynamic equilibrium,18 diminish thrombotic propensity,448 alleviate endothelial oxidative stress,449 attenuate inflammatory processes,450 and foster a favorable balance of the gut microbiota,451 all of which collectively contribute to the salutary effects of these agents in patients with AS.”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [18]
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057
Margulies, K. B., Hernandez, A. F., Redfield, M. M., Givertz, M. M., Oliveira, G. H., Cole, R., Mann, D. L., Whellan, D. J., Kiernan, M. S., Felker, G. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.10260 · Cited by 706
Jorsal, A., Kistorp, C., Holmager, P., Tougaard, R. S., Nielsen, R., Hänselmann, A., Nilsson, B., Møller, J. E., Hjort, J., Rasmussen, J., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.657 · Cited by 592
Self-citationRelationships Between Gastric Emptying, Postprandial Glycemia, and Incretin Hormones
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2013) · Diabetes Care · doi:10.2337/dc12-1609 · Cited by 335
Zhao, T., Parikh, P., Bhashyam, S., Bolukoglu, H., Poornima, I., Shen, Y.-T., & Shannon, R. P. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.100982 · Cited by 297
Nikolaidis, L. A., Elahi, D., Shen, Y.-T., & Shannon, R. P. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00347.2005 · Cited by 274
(1999) · PubMed · Cited by 230
Marinho, N. V. S., Keogh, B. E., Costa, D. C., Lammerstma, A. A., Ell, P. J., & Camici, P. G. (1996) · Circulation · doi:10.1161/01.cir.93.4.737 · Cited by 212
Mitochondrial Uncoupling: A Key Contributor to Reduced Cardiac Efficiency in Diabetes
Boudina, S., & Abel, E. D. (2006) · Physiology · doi:10.1152/physiol.00008.2006 · Cited by 199
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
Ussher, J. R., & Drucker, D. J. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00849-3 · Cited by 577
Lytvyn, Y., Bjornstad, P., Udell, J. A., Lovshin, J. A., & Cherney, D. Z. I. (2017) · Circulation · doi:10.1161/circulationaha.117.030012 · Cited by 459
GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms
Rizzo, M., Nikolic, D., Patti, A. M., Mannina, C., Montalto, G., McAdams, B. S., Rizvi, A. A., & Cosentino, F. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.05.012 · Cited by 152
Bornstein, M. R., Tian, R., & Arany, Z. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.06.003 · Cited by 105
Metadata
- Authors
- Nielsen, R., Jorsal, A., Iversen, P., Tolbod, L. P., Bouchelouche, K., Sørensen, J., Harms, H. J., Flyvbjerg, A., Tarnow, L., Kistorp, C., Gustafsson, I., Bøtker, H. E., & Wiggers, H.
- Affiliations
- Aarhus University Hospital (DK)
- Aarhus University (DK)
- Herlev Hospital (DK)
- Hvidovre Hospital (DK)
- Corresponding author
- Nielsen, Roni
- ORCID
- Venue
- Journal of Nuclear Cardiology
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 26
- Issue
- 2
- Pages
- 585-597
- ISSN
- 1071-3581 (ISSN-L)
- OpenAlex
- W2741776549
- Cited by
- 43
- References
- 40
- Citations by year
- 2026: 2 · 2025: 10 · 2024: 9 · 2023: 4 · 2022: 2 · 2021: 4 · 2020: 4 · 2019: 4
- FWCI
- 2.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- Journal of Nuclear Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Novo Nordisk Fonden (NNF16SA0024126)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- liraglutide, chronic heart failure, myocardial glucose uptake, myocardial blood flow, myocardial flow reserve, glucagon-like peptide-1 analogues, insulin resistance, oral glucose tolerance test, 18F-FDG PET, 15O-water PET, weight loss, HbA1c, non-diabetic patients
- MeSH terms
- Liraglutide, Administration, Oral, Aged, Blood Flow Velocity, Blood Glucose, Chronic Disease, Coronary Circulation, Denmark, Double-Blind Method, Echocardiography, Female, Glucose Tolerance Test, Heart Failure, Humans, Male, Middle Aged, Myocardium, Perfusion, Stroke Volume
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study. https://app.cochat.ai/papers/10.1007/s12350-017-1000-2
- The paper
- Nielsen, R., Jorsal, A., Iversen, P., Tolbod, L. P., Bouchelouche, K., Sørensen, J., Harms, H. J., Flyvbjerg, A., Tarnow, L., Kistorp, C., Gustafsson, I., Bøtker, H. E., & Wiggers, H. (2019). Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study. Journal of Nuclear Cardiology. https://doi.org/10.1007/s12350-017-1000-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.